Alector, Inc. Q4 FY2024 earnings call

• Strategic focus on discovering and developing disease-modifying therapies for neurodegenerative disorders like frontotemporal dementia, Alzheimer's, and Parkinson's. • Integrated biotechnology organization combining genetics, immunology, neuroscience, drug discovery, etc. • Two first-in-class late-stage clinical programs with GSK, five discovery programs. • Alector Brain Carrier (ABC) platform for enhanced brain delivery. • Latozinemab Phase 3 trial readout expected later in 2024, PROGRESS-AD Phase 2 trial completion in early 2025. • Preclinical pipeline includes anti-amyloid beta, GCase replacement, tau targeting, and Reelin modulator programs. • Financials: Q4 2024 collaboration revenue $54.2M vs $15.2M in 2023; R&D expenses Q4 2024 $46.5M vs $47.7M in 2023; G&A Q4 2024 $15M vs $14.9M in 2023. Annual 2024 collaboration revenue $100.6M vs $97.1M in 2023; R&D $185.9M vs $192.1M in 2023; G&A $59.6M vs $56.7M in 2023.

No detailed product segment financial performance with revenue contribution percentages provided in the transcript.

• 2025 collaboration revenue estimated between $5M and $15M. • Anticipated 2025 R&D expenses between $175M and $185M. • Anticipated 2025 general and administrative expenses between $55M and $65M.

Q: When considering the INFRONT study and patient enrollment, what gives confidence in enrolling the correct proportion of patients for clear separation between Latozinemab and placebo, and any caps on patient populations?

A: Gary Romano stated they intentionally enrolled a distribution of CDR-FTLD scores to target early symptomatic FTD granulin patients, capped CDR2s and stopped enrollment earlier to avoid overly progressed patients. Also mentioned sensitivity analysis on presymptomatic patients.

Q: On AL101, any read-through from INFRONT-3 and differences in mechanisms?

A: Gary Romano said mechanisms are different, with INFRONT-3 in FTD granulin and AL101 in Alzheimer's, but biomarkers and clinical outcomes will be key.

Q: Highlight key differences of Alector ABC platform vs others, and rationale for selecting ADP037 and ADP050 as first targets?

A: Sara Kenkare-Mitra said ABC platform is versatile and tunable. ADP037-ABC targets validated PyrGlu3 A beta epitope with active Fc for phagocytosis. ADP050-ABC is GCase replacement for Parkinson's with engineered stable enzyme.

Q: Thoughts on using siRNA vs ASOs and M&A for ABC technology?

A: Arnon Rosenthal said siRNA has potential advantages, and there's inbound interest in ABC technology with demand for the versatile platform.

Q: Power and data timing for INFRONT-3, and supporting biomarkers?

A: Gary Romano said INFRONT-3 is powered for 90% to detect 40% slowing, will have 96 weeks of data and long-term extension, and biomarkers like progranulin levels, fluid, and imaging biomarkers are considered.

Q: Enrichment in INFRONT-3 trial and competitive landscape for FTD?

A: Gary Romano discussed patient enrichment through site relationships, focus on symptomatic subjects, and differentiation by normalizing progranulin levels and showing biomarker changes and disease progression slowing.